Cambridge, UK,
We are thrilled to share an important milestone from our portfolio company, Monument Therapeutics, who have partnered with the Foundation for the National Institutes of Health (FNIH) to launch a clinical trial of MT1988, a novel treatment for cognitive impairment in schizophrenia.
Schizophrenia is one of the top 15 causes of disability worldwide, with symptoms ranging from hallucinations and delusions to severe cognitive impairment. Despite its impact, there are currently no effective treatments available for the cognitive symptoms, nor for individuals in the early “clinical high-risk” phase of the illness.
Monument’s pioneering approach, which combines innovative drug development with its proprietary digital biomarker, aims to transform early intervention and improve patient outcomes where the need is greatest. This is the first patient trial from Monument’s precision medicine pipeline, enrolling 150 participants, who will receive one of two dose levels of MT1988 or placebo over an eight-week treatment period. The trial is on track to begin dosing in the autumn of 2025.
At o2h Ventures, we are committed to supporting exceptional founders in building breakthrough science and advancing human health. To explore the portfolio we’ve built, please click here.
Sunil Shah, CEO of o2h Ventures, said:
We are really proud to support Monument and excited about this important milestone, which brings new hope to patients living with schizophrenia and their families. We look forward to continued support from o2h Ventures as Monument continues its journey through the clinic”
Jenny Barnett, CEO of Monument Tx, said:
This collaboration is a huge step towards a badly-needed treatment and we are delighted to work with such a prestigious group of investigators. We look forward to demonstrating not only the potential of this drug but also the value of our precision psychiatry approach.
About Monument Tx
Monument Therapeutics is a neuroscience-focused drug development company headquartered in Manchester, UK. It applies a unique novel drug development strategy, leveraging digital assessments of cognition to select patients suitable for treatment with new innovative drugs. For more information, please visit www.monumenttx.com.
About o2h Ventures
o2h Ventures is a biotech specialist fund manager based in Cambridge, UK, focused on backing innovative biotech companies that are transforming human health. We invest in pre-seed and seed-stage ventures developing novel therapeutics, pioneering medical technologies, and software or AI solutions that advance healthcare. Beyond funding, we actively support our portfolio with strategic guidance, industry connections, and operational expertise to help them scale.
Our team are recognised leaders in the biotech community, with over 20 years of experience as investors, board members, and hands-on participants in scientific innovation. o2h Ventures operates from our 2.7-acre Mill SciTech Park, where we have built a collaborative ecosystem to incubate and accelerate life sciences startups.To learn more about our portfolio and approach, please visit www.o2hventures.com.
